RxDoctor Payments Data

Edwin Urbi, MD

Psychiatry · Leesville, LANPI 1649264755

Payments from drug & device makers

$2,621in general payments, 2019–2025

Across 164 payments — averaging $15.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$457
  • Alkermes, Inc.$359
  • Acadia Pharmaceuticals Inc$280
  • Sunovion Pharmaceuticals Inc.$270
  • Otsuka America Pharmaceutical, Inc.$170
  • Neurocrine Biosciences, Inc.$163
  • plus $922 from 12 others

What the payments were for

  • Food & beverage$2,47895%
  • Education$1435%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,621 in reported general payments places this provider in the 75th percentile of 474 psychiatry providers in Louisiana.

See all psychiatry providers in Louisiana

Medicare billing

Part B allowed, 2024
$91,873
Medicare patients
344
Services billed
1,235

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate21$83,907
AustedoDeutetrabenazine11$26,196
VraylarCariprazine Hcl14$19,924
NuedextaDextromethorphan Hbr/Quinidine18$13,546
Risperdal ConstaRisperidone Microspheres13$9,932
JardianceEmpagliflozin19$6,379
Quetiapine Fumarate219$3,768
Olanzapine145$2,550
Risperidone147$2,488
Lurasidone Hcl11$2,156
Oxcarbazepine47$1,737
Divalproex Sodium60$1,695
Clonazepam75$1,629
Haloperidol41$1,461
Mirtazapine108$1,375

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$163$83,90721 claims
Teva Pharmaceuticals USA, Inc.Austedo$158$26,19611 claims
AbbVieVraylar$457$19,92414 claims
Johnson & JohnsonRisperdal Consta$156$9,93213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 474 psychiatry providers in Louisiana.

Other psychiatry in Leesville

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →